ReviewCurrent oncology (Toronto, Ont.)2023
Anal Cancer: The Past, Present and Future.
Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 6 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Prevalence, risk factors, and interventions for female sexual dysfunction after radiotherapy for anal cancer: a systematic review.British journal of cancer · 2026Pooled it
- SEOM-GEMCAD-TTD clinical guidelines for anal cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Outcomes of Anal Cancer Patients with Inflammatory Bowel Disease Treated with Curative Chemoradiotherapy: A Systematic Review of Current Evidence.Current oncology (Toronto, Ont.) · 2025Pooled it
- A systematic review on the role of interventional radiotherapy for treatment of anal squamous cell cancer: multimodal and multidisciplinary therapeutic approach.La Radiologia medica · 2024Pooled it
- Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Prognostic impact of anal cancer morphology on survival and local recurrence: A 20-year regional cohort study.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- More Than Just an Abscess: An Unusual Case of Anal Squamous Cell Carcinoma.ACG case reports journal · 2026Article
- Liquid Biopsy of HPV Cell-Free DNA Enables Blood-Based Early Detection and Molecular Stratification of HPV-Associated Cancer and Precancer Stages.medRxiv : the preprint server for health sciences · 2026Article
- Anal high-grade squamous intraepithelial lesions: identification, classification, and management.The British journal of surgery · 2026Review
- Anal Dysplasia: Epidemiology, Risk Factors, and Progression to Malignancy.Clinics in colon and rectal surgery · 2026Review
- Anal Dysplasia: A Review of Pathology with Focus on Current Terminology, Pathologic Diagnosis, and Diagnostic Challenges.Clinics in colon and rectal surgery · 2026Review
- Digital symptom monitoring and activity tracking in chemoradiation-lessons from the CAM experience.ESMO real world data and digital oncology · 2026Review
- Missed anal and anorectal tumors during endoscopic examinations: a ten-year retrospective study.BMC cancer · 2026Article
- Anal Squamous Cell Carcinoma with Bilateral Renal Metastases: A Rare Presentation with Literature Review.Current oncology (Toronto, Ont.) · 2026Review
- Intraocular metastasis from an anal squamous cell carcinoma: a case report.Journal of gastrointestinal oncology · 2025Article
- Anal cancer risk factors and HPV infection knowledge and awareness among Hispanic persons living with HIV in Puerto Rico.BMC public health · 2025Article
- [New possibilities of combining immunotherapy and radiotherapy in the definitive treatment of locally advanced cancer diseases].Magyar onkologia · 2025Review
- Real-world safety profile of mitomycin: signal detection and time-to-onset analysis from FDA adverse event reporting system and VigiAccess databases.International journal of clinical pharmacy · 2025Article
- "I just assumed that was the same as colon cancer." Lack of knowledge about anal HPV infection, anal cancer, and anal cancer screening in older MSM: a qualitative study.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anal cancer is a rare cancer that accounts for about 2% of all gastrointestinal tract malignancies. Among anal cancer, squamous cell cancer is the most common malignancy. The incidence of all stages of anal squamous cell cancer has been increasing. Human papillomavirus infection and immunosuppression are major risk factors for anal cancer. The management of anal cancer has evolved over the past several decades and continues to do so. Chemoradiation therapy remains the mainstay for treatment for most patients with early-stage disease, whereas systemic therapy is the primary treatment for patients with metastatic disease. Patients with persistent disease or recurrence following chemoradiation therapy are treated with salvage surgery. Access to novel cytotoxic combinations and immunotherapy has improved the outcomes of patients with advanced disease. This review provides an overview of advances in the management of anal cancer over the past two decades. This paper reviews the epidemiology, risk factors, pathology, diagnosis, and management of localized and advanced anal squamous cell cancer, highlights current knowledge gaps in the management of anal cancer, and discusses future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.